Skip to main content
. 2022 Nov 8;21:237. doi: 10.1186/s12933-022-01679-2

Fig. 1.

Fig. 1

Flow diagram of the study selection process HF heart failure, MRA mineralocorticoid receptor antagonist, SLGT2 sodium-glucose cotransporter-2, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, ARNI angiotensin receptor neprilysin inhibitor, MRA mineralocorticoid receptor antagonist